Danish Medicines Council could be a roadblock for sclerosis drug Kesimpta
Kesimpta has not blown the council away, a draft assessment of the Genmab-developed drug’s clinical value suggests.
by mikkel aabenhus hemmingsen, translated by catherine brett
Although sclerosis drug Kesimpta has been on somewhat of a worldwide victory tour, and generated sales of almost DKK 1.5bn (USD 230m) in the first three quarters of this year, the Danish Medicines Council is not convinced of its advantages.
In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.
The US retail chain has stopped selling its own private label hearing aids – and until the next generation comes along, other hearing companies selling products via Costco are enjoying the empty shelf space.